X
[{"orgOrder":0,"company":"Pyros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pyros Pharmaceuticals Announces Positive Outcome of the European Decentralised Procedure for Approval of VIGZIP\u2122 (vigabatrin oral solution)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Pyros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pyros Pharmaceuticals: FDA Approves VIGAFYDE as Ready-to-Use Oral Solution","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"}]
Find Clinical Drug Pipeline Developments & Deals by Pyros Pharmaceuticals
Filters
Companies By Therapeutic Area
Details:
Vigafyde (vigabatrin) is approved as monotherapy for pediatric patients with refractory complex partial seizures or infantile spasms in patients 1 month to 2 years of age.
Lead Product(s):
Vigabatrin
Therapeutic Area: Neurology
Product Name: Vigafyde
Highest Development Status: Phase IV
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 17, 2024
Details:
Vigzip (vigabatrin) is a Gamma-amino-N-butyrate transaminase inhibitor, which is indicated for the treatment of patients with infantile spasms (West's syndrome).
Lead Product(s):
Vigabatrin
Therapeutic Area: Neurology
Product Name: Vigzip
Highest Development Status: Phase IV
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 15, 2024